Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.
tk1sc provided MEP design for this 17,105 SF R&D tenant improvement space which included 6,944 SF of Lab and Lab Support space, including a process laboratory with redundant infrastructure, 5,648 SF of Private & Open Office, 2,420 SF Common Areas, Rooms, break areas, reception/lobby, mail and copy rooms.
Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.
tk1sc provided MEP design for this 17,105 SF R&D tenant improvement space which included 6,944 SF of Lab and Lab Support space, including a process laboratory with redundant infrastructure, 5,648 SF of Private & Open Office, 2,420 SF Common Areas, Rooms, break areas, reception/lobby, mail and copy rooms.
Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.
tk1sc provided MEP design for this 17,105 SF R&D tenant improvement space which included 6,944 SF of Lab and Lab Support space, including a process laboratory with redundant infrastructure, 5,648 SF of Private & Open Office, 2,420 SF Common Areas, Rooms, break areas, reception/lobby, mail and copy rooms.
Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.
tk1sc provided MEP design for this 17,105 SF R&D tenant improvement space which included 6,944 SF of Lab and Lab Support space, including a process laboratory with redundant infrastructure, 5,648 SF of Private & Open Office, 2,420 SF Common Areas, Rooms, break areas, reception/lobby, mail and copy rooms.